Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Cangrelor's effects on heart function during heart procedures

Official title: Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention

Run by Federico II University · NCT06089577 · Data updated 2026-11-12

This study is testing if a new heart medication called Cangrelor can better protect the small blood vessels in the heart during procedures for patients with chronic heart issues compared to the usual treatment.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment80 (estimated)
SponsorFederico II University
Academic / other
Locations2 sites (Ferrara and 1 other locations)
StatusRecruiting
StartedNovember 1, 2023
Main results expectedOctober 2025
Study endsOctober 2026
Registry record updatedMarch 13, 2025
Trial IDNCT06089577 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults with chronic coronary syndromes who are naive to P2Y12 inhibitors and require elective PCI for intermediate coronary artery stenoses.

Probably not a fit

Patients with acute coronary syndromes or those already on P2Y12 inhibitors will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the impact of Cangrelor, an intravenous antiplatelet medication, on coronary microvascular dysfunction in patients with chronic coronary syndromes undergoing elective percutaneous coronary interventions (PCI). It compares the efficacy of Cangrelor to standard treatment with Clopidogrel in preventing microvascular damage during these procedures. Patients will be monitored for changes in coronary flow reserve and index of microcirculatory resistance before and after PCI. The goal is to determine if Cangrelor can provide better protection for the heart's microcirculation during these interventions.

Why it matters

Potential benefit: If successful, this study could lead to improved heart function and reduced symptoms for patients undergoing PCI.

How similar studies have gone: While the use of Cangrelor is established, this specific application in elective PCI for chronic coronary syndromes is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult patients;
* Signed Informed Consent;
* Chronic coronary syndromes;
* P2Y12-inhibitors naive patients;
* Elective PCI of a functionally significant (FFR ≤ 0.80) de-novo intermediate coronary artery stenoses in a major vessel;

Exclusion Criteria:

* Underaged patients;
* Acute Conorary Syndromes;
* Already on treatment with P2Y12-inhibitors;
* Heart failure with severe reduction of the left ventricle ejection fraction (LVEF \< 30%);
* Subtotal occlusion (diameter stenosis \> 90%) of the target lesion;

Where it's running

  • Division of Cardiology - Federico II University Hospital
    Naples, Italy
    Recruiting
  • Division of Cardiology, University Hospital of Ferrara
    Ferrara, Italy
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.